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htcense.Abstract Rationale: It has long been known that COPD causes polycythemia secondary to eryth-
rocytosis caused by hypoxia present in advanced cases of COPD. However, it was shown in several
studies that some COPD patients had anemia rather than erythrocytosis. Revealing the changes
which occur in erythropoiesis in response to COPD was the aim of the current study.
Methods: 41 COPD patients of different groups according to the inclusion and exclusion criteria
and ten healthy control subjects age and sexmatchedwere enrolled in the study. For all, history taking
and full Clinical exam were performed, also ABGs, PFT (spirometry), routine labs (CBC, liver and
renal function) and determination of EPO should be performed on human serum by ELISA.
Results: Showed that the erythropoietin level was 15.24 ± 2.6 in stage 1, 22.61 ± 5.68 in stage 2,
33.59 ± 4, in stage 3, then 17.9 ± 3.3 in stage 4. Also the total percentage of anemia inCOPDpatients
was 46.3% (19/41), in comparison to 51.3% (21/41) non anemic and 2.4% (1/41) polycythemic.
And that the percentage of anemia was 27.3% in stage 1, followed by 38.0% in stage 2, 100% in
stage 3 then dropped to 58.33% in stage 4 with emergence of polycythemia in 8.33% of cases.
Conclusion: Although COPD was thought to cause polycythemia, the current study showed that
almost half of patients have anemia, and polycythemia occurred only in the advanced stages.
It also appeared that response to erythropoietin in COPD is probably blunted especially with
increased severity of the condition. This might be considered as a contributing factor in the develop-
ment of anemia in COPD which is considered as anemia of chronic disease.
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COPD is a major cause of chronic morbidity and mortality
throughout the world. Many people suffer from this disease
for years, and die prematurely from it or its complications [1].
It was estimated that 6% of the adult population were diag-
nosed as having COPD [2]. COPD was estimated to becomeis. Production and hosting by Elsevier B.V.
.10.026
54 R.I. El-Korashy et al.the third leading cause of death and ﬁfth cause of disability by
the year 2020 [3].
Although the GOLD 2011 deﬁnition of COPD did not
point to the extrapulmonary consequences of COPD as the
previous deﬁnition; still COPD might be considered a disorder
associated with extrapulmonary effects caused by comorbidi-
ties that are either secondary to inﬂammatory burden of
COPD or occurring in association with COPD due to sharing
of same risk factors [4].
It has long been known that COPD causes polycythemia sec-
ondary to erythrocytosis caused by hypoxia present in advanced
cases of COPD [5]. However, it was shown in several studies that
some COPD patients had anemia rather than erythrocytosis
[6,7]. Several hypotheses were proposed for this ﬁnding: for
example it was thought that the inﬂammatory burden of COPD
caused anemia of chronic disorders due to the effects of IL-1 and
TNF-a (anemia in COPD), also CRP and IL-6 [8]. This might
occur through shortened RBC survival, iron homeostasis dys-
regulation and impaired bone marrow erythropoietic response
[3]. Nutritional derangements in COPD patients were proposed
as a cause for anemia [9]. Also, tobacco smoking and its role in
oxidative stress has a role in RBCs production [10]. Lastly, the
role of comorbidities frequently encountered in COPD patients
as upper GI bleeding and folate deﬁciency was proposed how-
ever they were largely related to smoking also [7].
EPO is an endogenous glycoprotein hormone that serves as
the primary stimulus for erythropoiesis. The kidney is the pri-
mary site of EPOproduction, but the liver also produces the hor-
mone. EPOacts in the bonemarrow, where it promotes terminal
differentiation of progenitor cells into erythrocytes [11].
Diminished arterial oxygen content associated with anemia
or hypoxia is the major stimulus for EPO production and usu-
ally produces an exponential increase [12].
Ninety percent of EPO is produced in the peritubular cells
of the adult kidney in response to a decrease in tissue oxygen-
ation [13].
There is evidence indicating that the protein on these cells
which detects oxygen saturation of the blood is a heme-con-
taining moiety [14]. As the pO2 of the plasma, a function of
the hematocrit decreases, EPO concentration will increase [15].
The hematocrit is one of themost precisemethods of determin-
ing the degree of anemia or polycythemia (excessive amount of red
bloodcells) [16].Thehematocrit represents the volumeof redblood
cells in 100 ml of blood and is therefore reported as a percentage
[17]. Anemia is not a disease, but a term indicating insufﬁcient
hemoglobin to deliver oxygen to the cells. It is always a secondary
phenomenon [3]. Optimum values in an adult male are: Hemoglo-
bin 14–18 gm/dL and hematocrit 40.0% to 54.0% [18].
Rationale
There is a debate about the changeswhichoccur in erythropoiesis
in response to COPD. Some patients have anemia and others
have polycythemia, thus the study was performed to assess the
changes in erythropoietin in COPD patients in different stages.
Subjects and methods
This study was performed in Kasr Al-Aini hospital, Cairo Uni-
versity. The study included 51 subjects, 41 COPD patients of
different groups and ten healthy control subjects, age matched.Inclusion criteria:
– Patients diagnosed as COPD and categorized according to
the GOLD criteria 2011.
Exclusion criteria:
 History of asthma.
 History of malignancy or haematologic disorder.
 Systematic or autoimmune disorder.
 Thyroid disease.
 Liver cirrhosis.
 Heart failure (ejection fraction <55%).
 History of gastrointestinal or other hemorrhage.
 Renal failure (serum creatinine >1 gm/dL).
 Blood transfusion in the last 4 months.
For all subjects the following were done.
History taking and full Clinical exam.
Arterial blood gases.
Pulmonary function test; spirometry.
Routine labs (CBC, liver and renal function).
The determination of EPO should be performed on human
serum by ELISA.
Collect 1 mm of whole blood without anticoagulantion in
the morning between 7:30 a.m. to 12:00 noon, because diurnal
variation of erythropoietin has been reported [19,20]. Allow
blood to clot between 2 and 8 C. Then, the serum should be
promptly separated, preferably in a refrigerated centrifuge,
and stored at 15 C or lower. Serum samples frozen at
15 C are stable for up to 12 months [21].
Results
This study was performed in Kasr Al Aini hospital in collabo-
ration with the Clinical pathology department, and Biochemis-
try department in the Faculty of Biotechnology, MUST.
The study included 51 male subjects divided as 41 COPD
patients of different groups and 10 healthy control subjects.
Discussion
The study was aiming at assessment of the erythropoietin
changes in different stages of COPD as COPD is traditionally
associated with polycythemia [7] also the assumption that ane-
mia frequently occurs in patients with COPD [8]
51 subjects were included in this study, divided into 41
COPD male patients aged 56. 64 + 7.04 selected according
to the inclusion and exclusion criteria mentioned before and
10 healthy age matched males as control group.
The descriptive data in Table 1 showed that the mean
hemoglobin for COPD cases was 13.82 ± 1.95 g/dL while
for the control it was 14 ± 1.27 g/dl with no statistical signif-
icant. Mean value of Hematocrit was 42.1 ± 6.09 for COPD
and 43.8 ± 3.19 for control and again result was not statisti-
cally signiﬁcant. However oxygenation parameters in ABGs
showed statistically signiﬁcant difference between the COPD
patients and the control group as PaO2 was 58.56 ± 16.05
and 81.5 ± 2.54 for COPD cases and control, respectively
and SaO2 was 84.9 ± 14.7 and 96.80 ± 1.40 for COPD cases
and control respectively.
Table 1 Comparison between mean of different parameters in COPD cases and healthy control.
COPD cases group Healthy controls Mann–Whitney test
U value P value
Age 56.65 ± 7.04 53.60 ± 9.3 138 0.481
Hgb 13.82 ± 1.95 14 ± 1.27 127 0.316
Rbcs 4.84 ± 0.88 5.11 ± 0.46 156 0.829
Hct 42.1 ± 6.09 43.8 ± 3.19 163 0.978
Ph 7.42 ± 0.55 7.40 ± 0.011 103 0.097062
PCO2 44 ± 14.94 40.40 ± 1.96 109 0.136405
PO2 58.56 ± 16.05 81.5 ± 2.54 15 0.000055
SO2 84.9 ± 14.7 96.80 ± 1.40 20 0.000095
Signiﬁcant at p level < 0.05.
Table 3 Correlation between different parameters in control group.
Erythropoietin CC P value HB CC P value Hct CC P value
Age 0.80 0.017 Age 0.63 0.092 Age 0.40 0.32
Ph 0.32 0.445 Ph 0.50 0.20 Ph 0.32 0.45
PCO2 0.20 0.63 PCO2 0.6 0.09 PCO2 0.80 0.017
PO2 0.80 0.017 PO2 0.316 0.445 PO2 0.2 0.64
SO2 0.80 0.017 SO2 0.316 0.445 SO2 0.2 0.64
Signiﬁcant correlation if p< 0.05.
Table 4 Correlation between different parameters in COPD patients.
Erythropiotin CC P value HB CC P value Hct CC P value
Age 0.12 0.12 Age 0.17 0.28 Age 0.19 0.24
Ph 0.18 0.26 Ph 0.46 0.002 Ph 0.46 0.002
PCo2 0.21 0.18 PCo2 0.24 0.14 PCo2 0.338 0.03
PO2 0.031 0.85 PO2 0.15 0.34 PO2 0.19 0.24
SO2 0.002 0.99 SO2 0.18 0.26 SO2 0.21 0.18
GOLD staging 0.043 0.79 GOLD staging 0.17 0.28 GOLD staging 0.07 0.68
Signiﬁcant correlation if p< 0.05.
Table 2 Comparison between the erythropoietin levels in different COPD stages.
No of cases Gold stages Kruskal–Wallis test
Stage 1 Stage 2 Stage 3 Stage 4
11 13 5 12 Chi-square p-value
Erythropoietin mean ± SD 15.24 ± 2.6 22.61 ± 5.68 33.59 ± 4 17.09 ± 3.3
Erythropoietin median (IQR) 6.87 (2.04  19.5) 4.46 (2.75  11.23) 6.5 (3.06  77.68) 5.79 (4.41  64.75) 0.912 0.823
Signiﬁcant difference at p< 0.05.
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was a statistically signiﬁcant correlation for erythropoietin
with age, PaO2 and SaO2. However there was no statistically
signiﬁcant correlation between the erythropoietin level and
other parameters in COPD patients as shown in Table 4. This
led to the assumption that the factors that normally affect
erythropoietin production are no more effective; thus it could
be postulated that there would be a blunted response of eryth-
ropoietin to stimuli in COPD.
This may be explained by the presence of a two opposing
forces, one in its way to increase the production in response
to hypoxia resulting in polycythemia. The other one being achronic disease with systemic inﬂammatory burden, there is
an impact on bone marrow and kidneys decreasing erythropoi-
etin and production of RBCs [22]. Earlier studies showed that
there is an apparent lack of polycythaemic response to hypox-
aemia in COPD [23], John et al., found that there was a signif-
icant inverse correlation of haemoglobin versus erythropoietin,
indicating the presence of erythropoietin resistance. The asso-
ciation of inﬂammation and erythropoietin resistance is typical
of anemia of chronic disease [8].
COPD patients were divided into four stages according to
the GOLD 2011 and erythropoietin was correlated to degree
of severity of COPD in Table 2. And though the results were
Figure 1 Comparison between the mean hematocrite, hemoglo-
bin, and erythropiotin in different stages of COPD: Hct measured
in percent. Hb measured in g/dl. Erythropoietin measured in mU/
ml.
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erythropoietin remains low (15.24 mU/ml) and increases grad-
ually throughout stage two (22.61 mU/ml) to reach a maxi-
mum level in stage three (33.59 mU/ml). Then a decrease
followed in stage four (17.09 mU/ml) as shown also in Fig. 1.
On reﬂecting these changes on the routinely measured
parameters of complete blood picture, the percentage of anemia
in stage 1 was 27.3% and increased to 30.8% in stage 2, reaching
100% in stage 3 dropping again to 58.33% in stage 4. This
pattern occurs with hematocrit changes as shown in Fig. 1.
This picture reﬂects an increase in the erythropoietin
throughout COPD stages in response to increase percentage
of anemia throughout the same stages till a certain point where
evident normalization of the hemoglobin level occurs in stage 4
associated with the appearance of polycythemia with second-
ary drop in the erythropoietin level. So, it would be possible
that the normalization of hemoglobin may be due to phasic
change in hemoglobin levels from anemia to polycythemia
passing through normal levels of hemoglobin rather than
improvement of hemoglobin.
This was also explained by the fact that with worsening of
the condition there may be increased blunting of response to
erythropoietin due to inﬂammatory burden as the plasmaTable 5 Pattern of hemoglobin levels in different COPD stages.
COPD stages Hb
Anemic Normal
No % of stage No
I 3 27.3 8
II 4 30.8 9
III 5 100 0
IV 7 58.33 4
Total and percentage 19 46.3 21levels of erythropoietin are reduced in relation to a burst of
systemic inﬂammation [24,25]. However anemia of chronic dis-
ease was proposed as a cause for anemia in COPD patients and
inﬂammation may not be the only cause as renal impairment,
even with normal creatinine level may cause decreased produc-
tion of erythropoietin [26].
Polycythemia may be caused by acidosis, whether meta-
bolic due lactic acidosis or respiratory due to chronic respira-
tory failure [27], and not only due to hypoxia which itself can
cause lactic acidosis and produces a vicious circle with inﬂam-
mation and oxidative stress [28].
In a similar study performed in Iran, the authors worked on
80 patients with mean age 66.48 ± 11.55 and found anemia in
13 of the 80 patients (16%), while in the study in hand the per-
centage of anemia in COPD patients was 46.3% (21 patients)
of the COPD patients had anemia (<13.5 g/dL) as shown in
Table 5 [7].
In a study performed by John et al., anemia was diagnosed in
13% of 101 COPD patients [8]. All anemic COPD patients
showed elevated erythropoietin levels (41.8 ± 25.4 U/L vs
16.3 ± 2.9 U/L); with a signiﬁcant inverse correlation of hemo-
globin versus erythropoietin (p< 0.01) [8]. This ﬁnding supports
the ideaof increase the erythropoietinwithanemia as happened in
COPD stages 1, 2, and 3 according to the GOLD, 2011.
Conclusion
Although COPD was thought to cause polycythemia, the cur-
rent study showed that almost half of patients have anemia,
and polycythemia occurred only in the advanced stages. It also
appeared that reponse to erythropoietin in COPD was proba-
bly blunted especially with increased severity of the condition.
This might be considered as a contributing factor in the devel-
opment of anemia in COPD which was considered as anemia
of chronic disease.
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